1
|
Pagès M, Debily M, Fina F, Jones DTW, Saffroy R, Castel D, Blauwblomme T, Métais A, Bourgeois M, Lechapt‐Zalcman E, Tauziède‐Espariat A, Andreiuolo F, Chrétien F, Grill J, Boddaert N, Figarella‐Branger D, Beroukhim R, Varlet P. The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases. Neuropathol Appl Neurobiol 2022; 48:e12834. [PMID: 35836307 PMCID: PMC9542977 DOI: 10.1111/nan.12834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 05/24/2022] [Accepted: 07/07/2022] [Indexed: 11/28/2022]
Abstract
AIMS Dysembryoplastic neuroepithelial tumour (DNT) is a glioneuronal tumour that is challenging to diagnose, with a wide spectrum of histological features. Three histopathological patterns have been described: specific DNTs (both the simple form and the complex form) comprising the specific glioneuronal element, and also the non-specific/diffuse form which lacks it, and has unclear phenotype-genotype correlations with numerous differential diagnoses. METHODS We used targeted methods (immunohistochemistry, fluorescence in situ hybridisation and targeted sequencing) and large-scale genomic methodologies including DNA methylation profiling to perform an integrative analysis to better characterise a large retrospective cohort of 82 DNTs, enriched for tumours that showed progression on imaging. RESULTS We confirmed that specific DNTs are characterised by a single driver event with a high frequency of FGFR1 variants. However, a subset of DNA methylation-confirmed DNTs harbour alternative genomic alterations to FGFR1 duplication/mutation. We also demonstrated that a subset of DNTs sharing the same FGFR1 alterations can show in situ progression. In contrast to the specific forms, "non-specific/diffuse DNTs" corresponded to a heterogeneous molecular group encompassing diverse, newly-described, molecularly distinct entities. CONCLUSIONS Specific DNT is a homogeneous group of tumours sharing characteristics of paediatric low-grade gliomas: a quiet genome with a recurrent genomic alteration in the RAS-MAPK signalling pathway, a distinct DNA methylation profile and a good prognosis but showing progression in some cases. The "non-specific/diffuse DNTs" subgroup encompasses various recently described histomolecular entities, such as PLNTY and diffuse astrocytoma, MYB or MYBL1 altered.
Collapse
Affiliation(s)
- Mélanie Pagès
- GHU‐Paris – Sainte‐Anne Hospital, Department of NeuropathologyParis UniversityParisFrance
- Department of GeneticsInstitut CurieParisFrance
- SIREDO Paediatric Cancer CenterInstitut CurieParisFrance
- INSERM U830, Laboratory of Translational Research in Paediatric OncologyInstitut CurieParisFrance
- Paris Sciences Lettres Research UniversityParisFrance
| | - Marie‐Anne Debily
- Molecular Predictors and New Targets in Oncology, INSERM U981, Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
- Département de Biologie, Univ. EvryUniversité Paris‐SaclayEvryFrance
| | - Frédéric Fina
- APHM, CHU TimoneService d'Anatomie Pathologique et de NeuropathologieMarseilleFrance
| | - David T. W. Jones
- Pediatric Glioma ResearchHopp Children's Cancer Center (KiTZ)HeidelbergGermany
- Pediatric Glioma Research GroupGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Raphael Saffroy
- Oncogenetics Department, Assistance Publique‐Hôpitaux de Paris, Paul Brousse HospitalUniversité Paris‐SaclayVillejuifFrance
| | - David Castel
- Molecular Predictors and New Targets in Oncology, INSERM U981, Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
- Département de Biologie, Univ. EvryUniversité Paris‐SaclayEvryFrance
| | - Thomas Blauwblomme
- Pediatric Neurosurgery Department, AP‐HPHôpital Universitaire Necker‐Enfants MaladesParisFrance
- Université de Paris‐ CitéParisFrance
| | - Alice Métais
- GHU‐Paris – Sainte‐Anne Hospital, Department of NeuropathologyParis UniversityParisFrance
| | - Marie Bourgeois
- Pediatric Neurosurgery Department, AP‐HPHôpital Universitaire Necker‐Enfants MaladesParisFrance
| | | | | | - Felipe Andreiuolo
- Department of NeuropathologyInstituto Estadual do Cérebro Paulo NiemeyerRio de JaneiroBrazil
- Pathology Division, D'Or Research Institute (IDOR)D'Or Hospitals NetworkRio de JaneiroBrazil
| | - Fabrice Chrétien
- GHU‐Paris – Sainte‐Anne Hospital, Department of NeuropathologyParis UniversityParisFrance
- Université de Paris‐ CitéParisFrance
| | - Jacques Grill
- Molecular Predictors and New Targets in Oncology, INSERM U981, Gustave RoussyUniversité Paris‐SaclayVillejuifFrance
- Département de Biologie, Univ. EvryUniversité Paris‐SaclayEvryFrance
- Department of Pediatric and Adolescent OncologyInstitut Gustave RoussyVillejuifFrance
| | - Nathalie Boddaert
- Pediatric Radiology Department, AP‐HPHôpital Universitaire Necker‐Enfants MaladesParisFrance
- INSERM ERL UA10Université de ParisParisFrance
- Institut ImagineUniversité de Paris, UMR 1163ParisFrance
| | - Dominique Figarella‐Branger
- APHM, CHU TimoneService d'Anatomie Pathologique et de NeuropathologieMarseilleFrance
- Institute of NeuroPhysiopatholyAix‐Marseille Univ, CNRS, INPMarseilleFrance
| | - Rameen Beroukhim
- Department of Medical OncologyDana‐Farber Cancer InstituteBostonMassachusettsUSA
- Cancer ProgramBroad InstituteCambridgeMassachusettsUSA
- Department of MedicineHarvard Medical SchoolBostonMassachusettsUSA
| | - Pascale Varlet
- GHU‐Paris – Sainte‐Anne Hospital, Department of NeuropathologyParis UniversityParisFrance
| |
Collapse
|
2
|
Sarri B, Appay R, Heuke S, Poizat F, Franchi F, Boissonneau S, Caillol F, Dufour H, Figarella‐Branger D, Giovaninni M, Rigneault H. Observation of the compatibility of stimulated Raman histology with pathology workflow and genome sequencing. Translational Biophotonics 2021. [DOI: 10.1002/tbio.202000020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Affiliation(s)
- Barbara Sarri
- Aix Marseille University CNRS, Centrale Marseille, Institut Fresnel Marseille France
- Lightcore Technologies Cannes France
| | - Romain Appay
- Aix Marseille University CNRS, Centrale Marseille, Institut Fresnel Marseille France
- Aix‐Marseille University APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d' Anatomie Pathologique et de Neuropathologie Marseille France
| | - Sandro Heuke
- Aix Marseille University CNRS, Centrale Marseille, Institut Fresnel Marseille France
| | - Flora Poizat
- Institut Paoli‐Calmettes Endoscopy and Gastroenterology Department Marseille France
| | - Florence Franchi
- Institut Paoli‐Calmettes Endoscopy and Gastroenterology Department Marseille France
| | - Sébastien Boissonneau
- Aix‐Marseille University APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d' Anatomie Pathologique et de Neuropathologie Marseille France
| | - Fabrice Caillol
- Institut Paoli‐Calmettes Endoscopy and Gastroenterology Department Marseille France
| | - Henry Dufour
- Aix‐Marseille University APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d' Anatomie Pathologique et de Neuropathologie Marseille France
| | - Dominique Figarella‐Branger
- Aix‐Marseille University APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d' Anatomie Pathologique et de Neuropathologie Marseille France
| | - Marc Giovaninni
- Institut Paoli‐Calmettes Endoscopy and Gastroenterology Department Marseille France
| | - Hervé Rigneault
- Aix Marseille University CNRS, Centrale Marseille, Institut Fresnel Marseille France
- Lightcore Technologies Cannes France
| |
Collapse
|
3
|
Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella‐Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park S, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020; 30:844-856. [PMID: 32307792 PMCID: PMC8018152 DOI: 10.1111/bpa.12832] [Citation(s) in RCA: 300] [Impact Index Per Article: 75.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 03/16/2020] [Indexed: 02/03/2023] Open
Abstract
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT-NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles-relating to classification categories, approaches to classification, nomenclature, and grading-that the group hopes will also inform the future classification of CNS neoplasms.
Collapse
|
4
|
Heng MA, Padovani L, Dory‐Lautrec P, Gentet JC, Verschuur A, Pasquier E, Figarella‐Branger D, Scavarda D, André N. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma? Cancer Med 2016; 5:1542-5. [PMID: 27037940 PMCID: PMC4944881 DOI: 10.1002/cam4.699] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 01/29/2016] [Accepted: 02/16/2016] [Indexed: 01/22/2023] Open
Abstract
The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low-grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan-bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow-up of 23 months after the end of the bevacizumab-irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan-bevacizumab can improve progression-free survival in children with LGG.
Collapse
Affiliation(s)
- Marie Amélie Heng
- Service d'hématologie et Oncologie PédiatriqueCentre Hospitalo‐Universitaire Timone Enfants, AP‐HMMarseilleFrance
| | - Laetitia Padovani
- Service de RadiothérapieCentre Hospitalo‐Universitaire Timone EnfantsAP‐HMMarseilleFrance
| | - Philippe Dory‐Lautrec
- Service de RadiologieCentre Hospitalo‐Universitaire Timone EnfantsAP‐HMMarseilleFrance
| | - Jean Claude Gentet
- Service d'hématologie et Oncologie PédiatriqueCentre Hospitalo‐Universitaire Timone Enfants, AP‐HMMarseilleFrance
| | - Arnaud Verschuur
- Service d'hématologie et Oncologie PédiatriqueCentre Hospitalo‐Universitaire Timone Enfants, AP‐HMMarseilleFrance
- Metronomics Global Health InitiativeMarseilleFrance
| | - Eddy Pasquier
- Metronomics Global Health InitiativeMarseilleFrance
- Aix‐Marseille UniversitéINSERMCRO2 UMR_S 911Marseille13385France
| | - Dominique Figarella‐Branger
- Aix‐Marseille UniversitéINSERMCRO2 UMR_S 911Marseille13385France
- Service d'AnatomopathologieCentre Hospitalo‐Universitaire Timone EnfantsAP‐HMMarseilleFrance
| | - Didier Scavarda
- Service Neurochirurgie PédiatriqueCentre Hospitalo‐Universitaire Timone EnfantsAP‐HMMarseilleFrance
| | - Nicolas André
- Service d'hématologie et Oncologie PédiatriqueCentre Hospitalo‐Universitaire Timone Enfants, AP‐HMMarseilleFrance
- Metronomics Global Health InitiativeMarseilleFrance
- Aix‐Marseille UniversitéINSERMCRO2 UMR_S 911Marseille13385France
| |
Collapse
|
5
|
Figarella‐Branger D, Mokhtari K, Colin C, Uro‐Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage C, Eimer S, Polivka M, Vignaud J, Laquerriere A, Sevestre H, Lechapt‐Zalcman E, Quintin‐Roué I, Aubriot‐Lorton M, Diebold M, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel M, Labrousse F, Chenard M, Nguyen AT, Varlet P, Kemeny JL, Levillain P, Cazals‐Hatem D, Richard P, Delattre J. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathol 2015; 25:418-28. [PMID: 25407774 PMCID: PMC8029113 DOI: 10.1111/bpa.12227] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 11/07/2014] [Indexed: 12/26/2022] Open
Abstract
Diffuse adult high-grade gliomas (HGGs) with necrosis encompass anaplastic oligodendrogliomas (AOs) with necrosis (grade III), glioblastomas (GBM, grade IV) and glioblastomas with an oligodendroglial component (GBMO, grade IV). Here, we aimed to search for prognostic relevance of histological classification and molecular alterations of these tumors. About 210 patients were included (63 AO, 56 GBM and 91 GBMO). GBMO group was split into "anaplastic oligoastrocytoma (AOA) with necrosis grade IV/GBMO," restricted to tumors showing intermingled astrocytic and oligodendroglial component, and "GBM/GBMO" based on tumors presenting oligodendroglial foci and features of GBM. Genomic arrays, IDH1 R132H expression analyses and IDH direct sequencing were performed. 1p/19q co-deletion characterized AO, whereas no IDH1 R132H expression and intact 1p/19q characterized both GBM and GBM/GBMO. AOA with necrosis/GBMO mainly demonstrated IDH1 R132H expression and intact 1p/19q. Other IDH1 or IDH2 mutations were extremely rare. Both histological and molecular classifications were predictive of progression free survival (PFS) and overall survival (OS) (P < 10(-4) ). Diffuse adult HGGs with necrosis can be split into three histomolecular groups of prognostic relevance: 1p/19q co-deleted AO, IDH1 R132H-GBM and 1p/19q intact IDH1 R132H+ gliomas that might be classified as IDH1 R132H+ GBM. Because of histomolecular heterogeneity, we suggest to remove the name GBMO.
Collapse
Affiliation(s)
- Dominique Figarella‐Branger
- Service d'Anatomie Pathologique et de NeuropathologieHôpital de la TimoneAPHMMarseilleFrance
- INSERMCRO2 UMR_S 911Aix‐Marseille UniversitéMarseilleFrance
| | - Karima Mokhtari
- Département de Neuropathologie Raymond EscourolleGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
| | - Carole Colin
- INSERMCRO2 UMR_S 911Aix‐Marseille UniversitéMarseilleFrance
| | - Emmanuelle Uro‐Coste
- Service d'Anatomie Pathologique et Histologie‐CytologieHôpital RangueilCHU ToulouseToulouseFrance
- INSERM U1037Centre de Recherche en Cancérologie de ToulouseUniversité de ToulouseToulouseFrance
| | - Anne Jouvet
- Centre de Pathologie et de Neuropathologie EstHospices Civils de LyonBronFrance
| | - Caroline Dehais
- Service de Neurologie 2—MazarinGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
| | - Catherine Carpentier
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
| | - Chiara Villa
- Département de Neuropathologie Raymond EscourolleGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
- Service d'Anatomie PathologiqueHôpital FochSuresnesFrance
| | | | - Sandrine Eimer
- Service de Pathologie—NeuropathologieHôpital PellegrinCHU BordeauxBordeauxFrance
- EA2406Histologie et Pathologie Moléculaire des TumeursUniversité Bordeaux SegalenBordeauxFrance
| | - Marc Polivka
- Service d'Anatomie et Cytologie PathologiqueHôpital LariboisièreAP‐HPParisFrance
| | | | - Annie Laquerriere
- Laboratoire de PathologieHôpital Charles NicolleCHU RouenRouenFrance
| | - Henri Sevestre
- Service d'Anatomie et Cytologie PathologiquesCHU AmiensAmiensFrance
| | - Emmanuelle Lechapt‐Zalcman
- Service d'Anatomie PathologiqueHôpital de la Côte de NacreCHU CaenCaenFrance
- GIP CYCERONCERVOxyUMR 6301 ISTCTCNRSCaenFrance
| | | | | | - Marie‐Danièle Diebold
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital Robert DebréCHU ReimsReimsFrance
| | - Gabriel Viennet
- Service Anatomie et Cytologie PathologiquesHôpital Jean MinjozCHU BesançonBesançonFrance
| | - Clovis Adam
- Service Anatomie et Cytologie PathologiquesHôpital BicêtreAP‐HPKremlin‐BicêtreFrance
| | | | - Sophie Michalak
- Département Pathologie Cellulaire et TissulaireCHU AngersAngersFrance
| | - Valérie Rigau
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital Gui de ChaulliacCHU MontpellierMontpellierFrance
| | - Anne Heitzmann
- Service d'Anatomie PathologiqueHôpital la SourceCHR OrléansOrléansFrance
| | - Fanny Vandenbos
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital PasteurCHU NiceNiceFrance
| | - Fabien Forest
- Service d'Anatomie et Cytologie PathologiquesHôpital NordCHU Saint‐EtienneSaint‐EtienneFrance
| | | | | | | | - Marie‐Pierre Chenard
- Service d'Anatomie PathologiqueHôpital HautepierreCHU StrasbourgStrasbourgFrance
| | | | | | - Jean Louis Kemeny
- Service d'Anatomie et Cytologie PathologiquesHôpital Gabriel MontpiedCHU Clermont‐FerrandClermont‐FerrandFrance
| | - Pierre‐Marie Levillain
- Laboratoire d'Anatomie et Cytologie PathologiquesHôpital la MilétrieCHU PoitiersPoitiersFrance
| | | | - Pomone Richard
- Laboratoire d'Anatomie et Cytologie Pathologiques des FeuillantsToulouseFrance
| | - Jean‐Yves Delattre
- Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière (CRICM)UMR 7225Université Pierre et Marie Curie—Paris 6ParisFrance
- INSERM U1127ParisFrance
- Service de Neurologie 2—MazarinGroupe Hospitalier Pitié‐SalpêtrièreAP‐HPParisFrance
| | | |
Collapse
|
6
|
Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella‐Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng H, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014; 24:429-35. [PMID: 24990071 PMCID: PMC8029490 DOI: 10.1111/bpa.12171] [Citation(s) in RCA: 422] [Impact Index Per Article: 42.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present "white paper" catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided "ISN-Haarlem" guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be "layered" with histologic classification, WHO grade and molecular information listed below an "integrated diagnosis"; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.
Collapse
Affiliation(s)
- David N. Louis
- Department of PathologyMassachusetts General HospitalHarvard Medical SchoolBostonMAUSA
| | - Arie Perry
- Department of PathologyUniversity of California San FranciscoSan FranciscoCAUSA
| | - Peter Burger
- Department of PathologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - David W. Ellison
- Department of PathologySt. Jude Children's Research HospitalMemphisTNUSA
| | - Guido Reifenberger
- Department of NeuropathologyHeinrich Heine UniversityDuesseldorfGermany
- Clinical Cooperation Unit NeuropathologyGerman Cancer Consortium (DKTK)German Cancer Research Center (DKFZ)HeidelbergGermany
| | - Andreas von Deimling
- Clinical Cooperation Unit NeuropathologyGerman Cancer Consortium (DKTK)German Cancer Research Center (DKFZ)HeidelbergGermany
- Department of NeuropathologyInstitute of PathologyRuprecht‐Karls‐UniversityHeidelbergGermany
| | - Kenneth Aldape
- Department of PathologyPrincess Margaret HospitalTorontoCanada
| | - Daniel Brat
- Department of Pathology and Laboratory MedicineEmory University School of MedicineAtlantaGAUSA
| | | | - Charles Eberhart
- Department of PathologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | | | - Gregory N. Fuller
- Department of PathologyThe University of Texas M. D. Anderson Cancer CenterHoustonTXUSA
| | - Felice Giangaspero
- Department of RadiologicalOncological and Anatomo‐Pathological SciencesUniversity La SapienzaRome
- IRCCS NeuromedPozzilliItaly
| | - Caterina Giannini
- Department of Laboratory Medicine and PathologyMayo ClinicRochesterMNUSA
| | - Cynthia Hawkins
- Department of Paediatric Laboratory MedicineThe Hospital for Sick ChildrenUniversity of TorontoTorontoCanada
| | | | - Andrey Korshunov
- Clinical Cooperation Unit NeuropathologyGerman Cancer Consortium (DKTK)German Cancer Research Center (DKFZ)HeidelbergGermany
- Department of NeuropathologyHeidelberg University HospitalHeidelbergGermany
| | - Johan M. Kros
- Department of PathologyErasmus Medical CenterRotterdamThe Netherlands
| | - M. Beatriz Lopes
- Department of PathologyUniversity of Virginia School of MedicineCharlottesvilleVAUSA
| | - Ho‐Keung Ng
- Department of Anatomical Pathology and Cellular PathologyThe Chinese University of Hong KongHong Kong
| | - Hiroko Ohgaki
- International Agency for Research on Cancer (IARC)LyonFrance
| | - Werner Paulus
- Institute of NeuropathologyUniversity Hospital MünsterMünsterGermany
| | - Torsten Pietsch
- Institute of NeuropathologyBrain Tumor Reference CenterUniversity of BonnBonnGermany
| | - Marc Rosenblum
- Department of PathologyMemorial Sloan‐Kettering Cancer CenterNew YorkNYUSA
| | - Elisabeth Rushing
- Institute for NeuropathologyUniversity Hospital of ZurichZurichSwitzerland
| | | | | | - Pieter Wesseling
- Department of PathologyVU University Medical CenterAmsterdamThe Netherlands
- Department of PathologyRadboud University Medical CenterNijmegenThe Netherlands
| |
Collapse
|
7
|
Metellus P, Figarella‐Branger D, Guyotat J, Barrie M, Giorgi R, Jouvet A, Chinot O. Supratentorial ependymomas: Prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 2008; 113:175-85. [DOI: 10.1002/cncr.23530] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
8
|
Kros JM, Gorlia T, Kouwenhoven M, Collins P, Figarella‐Branger D, Giangaspero F, Giannini C, Mohktari K, Mork SJ, Paetau A, Reifenberger G, Bent MJ. Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. FASEB J 2007. [DOI: 10.1096/fasebj.21.5.a26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Johan M. Kros
- PathologyErasmus medical Centerdr. Molewaterplein 50, 3015GDRotterdamNetherlands
| | - Thierry Gorlia
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Mathilde Kouwenhoven
- PathologyErasmus medical Centerdr. Molewaterplein 50, 3015GDRotterdamNetherlands
| | - Peter Collins
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | | | - Felice Giangaspero
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Caterina Giannini
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Kharima Mohktari
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Sverre J. Mork
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Anders Paetau
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Guido Reifenberger
- EORTCBiostatistics, Avenue E. Mounierlaan, 83/11, 1200 BrusselsBrusselsBelgium
| | - Martin J. Bent
- PathologyErasmus medical Centerdr. Molewaterplein 50, 3015GDRotterdamNetherlands
| |
Collapse
|
9
|
Putzu G, Figarella‐Branger D, Bouvier‐Labit C, Liprandi A, Bianco N, Pellissier J. IMMUNOHISTOCHEMICAL LOCALIZATION OF CYTOKINES, C5B‐9 AND ICAM‐1 IN PERIPHERAL NERVE OF GUILLAIN‐BARRE SYNDROME. J Peripher Nerv Syst 2000. [DOI: 10.1111/j.1529-8027.2000.22-10.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ga Putzu
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| | - D Figarella‐Branger
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| | - C Bouvier‐Labit
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| | - A Liprandi
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| | - N Bianco
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| | - Jf Pellissier
- Journal of the Neurological Sciences 174: 16–21, 2000. Reprinted with permission from Elsevier Science BV
| |
Collapse
|